Abstract Body

Background: HIV-associated neurocognitive disorders (HAND) are a collection of neurological deficits characterized by cognitive, motor, and behavior abnormalities, and remains a significant problem in ART-treated infected individuals. Neurological injury in HAND is a consequence of both persistent immune activation and the release of neurotoxins, such as glutamate, by HIV-infected and/or activated macrophages and microglia. Previous studies have implicated several macrophage enzymes in these neurodegenerative processes, including the cytoprotective enzyme heme oxygenase-1 (HO-1), glutaminase isoforms, and indoleamine 2,3-dioxygenase (IDO), that are disturbed by HIV infection. Statins (HMG-CoA reductase inhibitors) have pleiotropic immunomodulatory effects independent from their cholesterol-lowering abilities, such as downregulating monocyte/macrophage activation and inflammation. Therefore, we hypothesized that statins would modulate the levels of proteins associated with inflammation and neurological injury in HIV-1 infected macrophages.

Methods: Primary monocyte-derived macrophages (MDM) were infected in vitro with the macrophage-tropic HIV-1 strain YU-2. After 4-8 days, following establishment of infection (verified by supernatant p24 Gag antigen), cells were treated with atorvastatin (10 μM). After 6-48 hours, cells were lysed and protein expression of HO-1, IDO, and glutaminase isoforms were assessed by Western blot analysis.

Results: HIV-1 infection of MDM reduced HO-1 and increased IDO protein expression, as previously reported. We found that treatment with atorvastatin for 12-24 hours on day 8 post-infection increased HO-1 protein expression, partially reversing the HIV-mediated reduction. Similarly, treatment with atorvastatin for 6 hours on day 4 post-infection increased the level of HO-1. In contrast, atorvastatin had no effect on two isoforms of glutaminase, KGA and GAC. Effects on IDO were modest and inconsistent.

Conclusions: Atorvastatin partially reverses the HIV-mediated reduction of HO-1 in macrophages. Brain and macrophage HO-1 deficiency in HIV-infection has been implicated in HAND pathogenesis. Thus, statin drugs through HO-1 induction could be useful as an adjunctive therapy for HAND in HIV-infected ART-treated individuals.